NCT06666712View on ClinicalTrials.gov

Chronic CED of TPT for Recurrent Malignant Glioma

PHASE1RecruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

June 30, 2028

Conditions
Brain Tumor, RecurrentMalignant Glioma (WHO Grade III or IV)IDH1/IDH2 Mutation
Interventions
DRUG

Topotecan

Topotecan (TPT) is a chemotherapeutic agent that is a topoisomerase inhibitor. This intervention is uniquely distinguished through its administration using an externalized catheter and external microinfusion pump (Convection-Enhanced Delivery)

Trial Locations (1)

10032

RECRUITING

Columbia University Irving Medical Center / NewYork-Presbyterian Hospital, New York

All Listed Sponsors
lead

Jeffrey N. Bruce

OTHER